Alinity m HR HPV Assay Fulfills Criteria for Human Papillomavirus Test Requirements in Cervical Cancer Screening Settings.
Adult
Colposcopy
Cytological Techniques
DNA, Viral
Early Detection of Cancer
/ methods
Female
Genotype
Humans
Mass Screening
Molecular Typing
/ methods
Papillomaviridae
/ classification
Papillomavirus Infections
/ complications
Reproducibility of Results
Uterine Cervical Neoplasms
/ diagnosis
Uterine Cervical Dysplasia
/ diagnosis
Alinity HPV
HPV assay
HPV primary screening
cervical cancer
genotyping
hc2
human papillomavirus
validation
Journal
Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564
Informations de publication
Date de publication:
23 12 2019
23 12 2019
Historique:
received:
11
07
2019
accepted:
20
10
2019
pubmed:
2
11
2019
medline:
21
7
2020
entrez:
1
11
2019
Statut:
epublish
Résumé
The Alinity m HR HPV assay (Alinity) is a novel human papillomavirus (HPV) assay that individually identifies genotypes HPV16, HPV18, and HPV45 while reporting on 11 other high-risk HPV (hrHPV) genotypes in two aggregates: HPV31/33/52/58 and HPV35/39/51/56/59/66/68. The clinical performance of Alinity for screening for cervical cancer was evaluated in population-based settings. For women aged ≥30 years, the clinical sensitivity (
Identifiants
pubmed: 31666369
pii: JCM.01120-19
doi: 10.1128/JCM.01120-19
pmc: PMC6935899
pii:
doi:
Substances chimiques
DNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2019 American Society for Microbiology.
Références
J Natl Cancer Inst. 2010 Oct 6;102(19):1478-88
pubmed: 20841605
Am J Clin Pathol. 2015 Sep;144(3):473-83
pubmed: 26276778
J Clin Virol. 2013 Nov;58(3):571-4
pubmed: 24051043
J Clin Virol. 2005 Mar;32 Suppl 1:S34-42
pubmed: 15753010
J Clin Virol. 2019 Nov;120:57-62
pubmed: 31569008
J Clin Virol. 2016 Mar;76 Suppl 1:S14-S21
pubmed: 26522865
BMJ. 2016 Oct 4;355:i4924
pubmed: 27702796
J Clin Virol. 2009 Jul;45 Suppl 1:S25-8
pubmed: 19651365
Vaccine. 2008 Mar 14;26 Suppl 1:A24-7
pubmed: 18642459
Clin Microbiol Infect. 2015 Sep;21(9):817-26
pubmed: 25936581
Lancet. 2014 Feb 8;383(9916):524-32
pubmed: 24192252
J Clin Microbiol. 2011 May;49(5):1721-9
pubmed: 21430098
BMJ. 2014 Jan 16;348:g130
pubmed: 24435414
Int J Cancer. 2015 Jul 1;137(1):193-203
pubmed: 25471319
J Infect Dis. 2011 Mar 15;203(6):814-22
pubmed: 21343148
Gynecol Oncol. 2015 Sep;138(3):573-8
pubmed: 26148763
Papillomavirus Res. 2016 Dec;2:112-115
pubmed: 29074170
Obstet Gynecol. 2016 Dec;128(6):1248-1257
pubmed: 27824767
J Clin Virol. 2016 Mar;76 Suppl 1:S3-S13
pubmed: 26601820
J Clin Virol. 2016 Mar;76 Suppl 1:S29-S39
pubmed: 26643051
Vaccine. 2008 Mar 14;26 Suppl 1:A16-23
pubmed: 18642468
Gynecol Oncol. 2015 Feb;136(2):178-82
pubmed: 25579107
Int J Cancer. 2015 Mar 1;136(5):1171-80
pubmed: 25043476
J Clin Microbiol. 2015 Jan;53(1):52-9
pubmed: 25339396
Int J Cancer. 2009 Feb 1;124(3):516-20
pubmed: 18973271
J Clin Microbiol. 2018 Oct 25;56(11):
pubmed: 30209184
Gynecol Oncol. 2015 Feb;136(2):189-97
pubmed: 25579108
J Clin Microbiol. 2017 Dec;55(12):3544-3551
pubmed: 29021152
Am J Clin Pathol. 2012 Jan;137(1):161-2; author reply 162-3
pubmed: 22180491
Eur J Cancer. 2011 Apr;47(6):864-71
pubmed: 21334200
Int J Cancer. 2016 Dec 1;139(11):2606-15
pubmed: 27509172
Int J Cancer. 2013 Feb 15;132(4):854-67
pubmed: 22752992
J Clin Oncol. 2012 Sep 1;30(25):3044-50
pubmed: 22851570
Int J Cancer. 2015 Jan 15;136(2):350-9
pubmed: 24842156
J Clin Virol. 2018 Jan;98:37-42
pubmed: 29241150
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593